戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nment, controlling for income per person and HIV seroprevalence.
2 IV transmission, even within an area of high HIV seroprevalence.
3 tion with high human immunodeficiency virus (HIV) seroprevalence (35%) to determine the prevalence of
4          The authors sought to determine the HIV seroprevalence among suicide victims in New York Cit
5 ethods may be useful in other areas in which HIV seroprevalence data among childbearing women and HIV
6                      Clinicians, using local HIV seroprevalence data and their knowledge of transmiss
7                                          The HIV seroprevalence declined from 15.2% in 1989 to 7.2% i
8 adjusted proportion was then contrasted with HIV seroprevalence estimates for the New York City gener
9 imately 0.038 to 0.059), contrasted with the HIV seroprevalence estimates for the New York City gener
10                                              HIV seroprevalence in ulcer patients was 6% (range by ci
11                                      Because HIV seroprevalence is at least 2 to 7% in "low-risk" gro
12 ally-assembled database for paired HSV-2 and HIV seroprevalence measures among FSWs.
13 ators in the community, the postintervention HIV seroprevalence of these groups, and linkage to care
14          In a second patient cohort of mixed HIV seroprevalence, plasma PIIINP concentration was incr
15                         We conclude that the HIV seroprevalence rate among patients hospitalized for
16                We enrolled 436 patients; the HIV seroprevalence rate was 2%.
17 High antenatal human immunodeficiency virus (HIV) seroprevalence rates ( approximately 30%) with low
18                                              HIV seroprevalence was high in women at the remand centr
19                                              HIV seroprevalence was remarkably high, ranging from 11%
20              There was a trend of increasing HIV seroprevalence with increasing frequency of rectal b
21 l zidovudine program in a setting with 12.5% HIV seroprevalence would reduce perinatal HIV incidence